Nivolumab + Carboplatin + Paclitaxel
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Oropharynx Squamous Cell Carcinoma
Conditions
Oropharynx Squamous Cell Carcinoma
Trial Timeline
Sep 5, 2019 → Jun 11, 2024
NCT ID
NCT03829722About Nivolumab + Carboplatin + Paclitaxel
Nivolumab + Carboplatin + Paclitaxel is a phase 2 stage product being developed by Bristol Myers Squibb for Oropharynx Squamous Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03829722. Target conditions include Oropharynx Squamous Cell Carcinoma.
What happened to similar drugs?
0 of 2 similar drugs in Oropharynx Squamous Cell Carcinoma were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03829722 | Phase 2 | Completed |
Competing Products
5 competing products in Oropharynx Squamous Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Nivolumab + Cetuximab | Eli Lilly | Phase 1/2 | 32 |
| ISA101b + Cemiplimab | Regeneron Pharmaceuticals | Phase 2 | 31 |
| ISA101b | Regeneron Pharmaceuticals | Phase 2 | 31 |
| Homeodent® + 1.4% Sodium Bicarbonate solution | Boiron | Phase 3 | 22 |
| SGX942 + Placebo | Soligenix | Phase 3 | 30 |